Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients
Authors:
Open Access
- 16 December 2015
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 76 (1) , 75-98
Abstract
HIV-1-infected patients with suppressed plasma viral loads often require changes to their antiretroviral (ARV) therapy to manage drug toxicity and intolerance, to improve adherence, and to avoid drug interactions. In patients who have never experienced virologic failure while receiving ARV therapy and who have no evidence of drug resistance, switching to any of the acceptable US Department of Health and Human Services first-line therapies is expected to maintain virologic suppression. However, in virologically suppressed patients with a history of virologic failure or drug resistance, it can be more challenging to change therapy while still maintaining virologic suppression. In these patients, it may be difficult to know whether the discontinuation of one of the ARVs in a suppressive regimen constitutes the removal of a key regimen component that will not be adequately supplanted by one or more substituted ARVs. In this article, we review many of the clinical scenarios requiring ARV therapy modification in patients with stable virologic suppression and outline the strategies for modifying therapy while maintaining long-term virologic suppression.Keywords
This publication has 133 references indexed in Scilit:
- Systematic Review of Antiretroviral-Associated Lipodystrophy: Lipoatrophy, but Not Central Fat Gain, Is an Antiretroviral Adverse Drug ReactionPLOS ONE, 2013
- SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral RegimenClinical Infectious Diseases, 2013
- Boosted protease inhibitor monotherapy in HIV-infected adults: outputs from a pan-European expert panel meetingAIDS Research and Therapy, 2013
- Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING StudyThe Journal of Infectious Diseases, 2012
- Bone Loss in the HIV-Infected Patient: Evidence, Clinical Implications, and Treatment StrategiesThe Journal of Infectious Diseases, 2012
- HIV-1 Integrase Inhibitor Resistance and Its Clinical ImplicationsThe Journal of Infectious Diseases, 2011
- Short‐Course Raltegravir Intensification Does Not Reduce Persistent Low‐Level Viremia in Patients with HIV‐1 Suppression during Receipt of Combination Antiretroviral TherapyClinical Infectious Diseases, 2010
- Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapyProceedings of the National Academy of Sciences, 2009
- Regimen Simplification to Atazanavir‐Ritonavir Alone as Maintenance Antiretroviral Therapy: Final 48‐Week Clinical and Virologic OutcomesThe Journal of Infectious Diseases, 2009
- HLA-B*5701 Screening for Hypersensitivity to AbacavirNew England Journal of Medicine, 2008